Evidence map›Paper›PMID 37858324›Full record

ArticleThe Lancet. Infectious diseases2024

Determinants of piperaquine-resistant malaria in South America.

Sachel Mok, David A Fidock

Abstract readComment
In one paragraph

Article in The Lancet. Infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Temporal and spatial dynamics ofbioRxiv : the preprint server for biology · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sachel MokCenter for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA.
David A FidockCenter for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: df2260@cumc.columbia.edu.

Funding

Defining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug ResistanceR37AI050234 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2018 to 2026
$4.4M
Defining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4M
Elucidating the molecular basis of piperaquine resistance in Plasmodium falciparumR01AI124678 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2016 to 2026
$4.3M
The genetic basis of emerging multidrug resistance in Plasmodium falciparum African malariaR01AI182318 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Sachel Mok · 2024 to 2026
$1.9M
NIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI124678NIAID NIH HHS R01 AI182318NIAID NIH HHS R37 AI050234
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AntimalarialsMalariaMalaria, FalciparumPiperazinesQuinolinesHumansSouth AmericaAntimalarialspiperaquinePiperazinesQuinolines

Identifiers

PMID37858324
PMCPMC10872569

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.